CSIMarket
 

Glaukos Corp  (GKOS)
Other Ticker:  
 

Glaukos's

Competitiveness


 

GKOS Sales vs. its Competitors Q4 2023







Revenue Growth Comparisons




Net Income Comparison




<<  GKOS Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Glaukos Corp Contracts

Glaukos Revolutionizes Glaucoma Treatment with FDA Approval of iDose TR and Sets Stage for Promising Growth in the Market


Glaukos Corporation Receives FDA Approval for iDose TR, Presenting Positive Growth Prospects in the Glaucoma Market
Glaukos Corporation, a leading ophthalmic medical technology and pharmaceutical company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases, has recently announced the approval of its New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA). This regulatory clearance allows Glaukos to introduce iDose TR, a single administration per eye of travoprost intracameral implant, into the market.
The primary indication for iDose TR is the reduction of intraocular pressure (IOP) in patients suffering from glaucoma, a condition characte...





Who are Glaukos Corp's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com